Finch Therapeutics Group, Inc.
Finch Therapeutics Group, Inc.（FNCH）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · FNCH · 截至 2026年6月9日
活动摘要
买入笔数
1
P-Purchase only
卖出笔数
4
近12个月
买卖比
0.25
Buy/Sell (by trades)
整体情绪
Finch Therapeutics Group, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月9日
FNCH 季度内部人买卖趋势
FNCH 内幕交易卖出 · FNCH 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 9, 2026
近期内幕交易记录
FNCH 高管卖出股份 · FNCH 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Jun 7, 2024 | SMISEK JEFFERY A Director | Gift | 383 | — | Form 4 |
| Jun 7, 2024 | SMISEK JEFFERY A Director | Gift | 384 | — | Form 4 |
| May 20, 2024 | SMISEK JEFFERY A Director | Gift | 3,750 | — | Form 4 |
| Mar 28, 2024 | SMISEK JEFFERY A Director | Sale | 1,600 | $4K | Form 4 |
| Mar 28, 2024 | SMISEK JEFFERY A Director | Sale | 6,642 | $17K | Form 4 |
| Nov 22, 2023 | SMISEK JEFFERY A Director | Sale | 1,470 | $5K | Form 4 |
| Jun 9, 2023 | Graf Susan E Director | Purchase | 5,010 | $1K | Form 4 |
| Feb 21, 2023 | Blaustein Marc COO | Sale | 4,619 | $2K | Form 4 |
| Oct 21, 2022 | Blaustein Marc COO | Sale | 3,636 | $5K | Form 4 |
| Oct 21, 2022 | Vittiglio Joseph Chief Business & Legal Officer | Sale | 3,636 | $5K | Form 4 |
| Jun 13, 2022 | Blaustein Marc COO | Award | 35,000 | — | Form 4 |
| Jun 13, 2022 | Vittiglio Joseph Chief Business & Legal Officer | Award | 35,000 | — | Form 4 |
| Mar 23, 2021 | SMISEK JEFFERY A Director | Purchase | 88,235 | $1.50M⚡ | Form 4 |
| Mar 23, 2021 | SMISEK JEFFERY A Director | Other | 272,245 | — | Form 4 |
| Mar 23, 2021 | SMISEK JEFFERY A Director | Other | 297,178 | — | Form 4 |
| Mar 23, 2021 | SMISEK JEFFERY A Director | Other | 141,928 | — | Form 4 |
| Mar 23, 2021 | SMISEK JEFFERY A Director | Other | 894,955 | — | Form 4 |
| Mar 23, 2021 | Haft Nicholas Director | Other | 366,093 | — | Form 4 |
| Mar 23, 2021 | Haft Nicholas Director | Other | 1,150,481 | — | Form 4 |
| Mar 23, 2021 | Haft Nicholas Director | Other | 1,064,466 | — | Form 4 |
| Mar 23, 2021 | Haft Nicholas Director | Purchase | 882,351 | $15.00M⚡ | Form 4 |
| Mar 23, 2021 | Haft Nicholas Director | Other | 212,893 | — | Form 4 |
| Mar 23, 2021 | Haft Nicholas Director | Other | 172,942 | — | Form 4 |
| Mar 23, 2021 | Haft Nicholas Director | Other | 143,831 | — | Form 4 |
| Mar 23, 2021 | FERRANTE DOMENIC J Director | Purchase | 102,941 | $1.75M⚡ | Form 4 |
Vittiglio Joseph
Chief Business & Legal Officer
日期
Oct 21
股数
3,636
均价
$1.39
总金额
$5K
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 FNCH 内幕交易
FNCH 内幕交易
Finch Therapeutics Group, Inc.（FNCH）内幕交易数据来源于公司内部人（包括FNCH）提交的SEC Form 4申报文件。过去12个月内，0位内部人向SEC提交了交易申报。FNCH内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Finch Therapeutics Group, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
FNCH 内幕交易 · 5个问题Finch Therapeutics Group, Inc.（FNCH）的内部人包括高管和董事，如FNCH等。过去12个月内，0位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 9, 2026